Literature DB >> 10933049

Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

S J Hughes1, M A Morse, C M Weghorst, H Kim, P B Watkins, F P Guengerich, M B Orringer, D G Beer.   

Abstract

The expression of cytochromes P450 (CYP) in Barrett's esophagus and esophageal squamous mucosa was investigated. Esophagectomy specimens from 23 patients were examined for CYP expression of CYP1A2, CYP3A4, CYP2C9/10, and CYP2E1 by immunohistochemical analysis, and the expression of CYP1A1, CYP3A4, CYP1B1, CYP2E1, and CYP2C9/10 in these tissues was further confirmed by reverse transcription polymerase chain reaction. Immunohistochemical analysis of esophageal squamous mucosa (n = 12) showed expression of CYP1A2, CYP3A4, CYP2E1, and CYP2C9/10 proteins, but it was noted that cells within the basal proliferative zone did not express CYPs. Immunohistochemical analysis of Barrett's esophagus (n = 13) showed expression of CYP1A2, CYP3A4, CYP2E1, and CYP2C9/10 that was prominent in the basal glandular regions, which are areas containing a high percentage of actively proliferating cells. Immunohistochemical staining for both proliferating cell nuclear antigen and the CYPs further supported the colocalization of CYP expression to areas of active cell proliferation in Barrett's esophagus, whereas in the esophageal squamous epithelium, CYP expression is limited to cells that are not proliferating. RT-PCR with amplification product sequence analysis confirmed CYP1A1, CYP3A4, CYP1B1, CYP2E1, and CYP2C9/10 mRNA expression in Barrett's esophagus. These data suggest that the potential ability of cells in Barrett's esophagus to both activate carcinogens and proliferate may be important risk factors affecting carcinogenesis in this metaplastic tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10933049      PMCID: PMC1508133          DOI: 10.1038/sj.neo.7900017

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  44 in total

1.  Malignant transformation of esophageal columnar epithelium.

Authors:  M M Berenson; R H Riddell; D B Skinner; J W Freston
Journal:  Cancer       Date:  1978-02       Impact factor: 6.860

Review 2.  Genes for cytochrome P-450 and their regulation.

Authors:  M Adesnik; M Atchison
Journal:  CRC Crit Rev Biochem       Date:  1986

Review 3.  Barrett's esophagus.

Authors:  S J Spechler; R K Goyal
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

5.  CYP3A gene expression in human gut epithelium.

Authors:  J C Kolars; K S Lown; P Schmiedlin-Ren; M Ghosh; C Fang; S A Wrighton; R M Merion; P B Watkins
Journal:  Pharmacogenetics       Date:  1994-10

6.  Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.

Authors:  R G Lee
Journal:  Am J Surg Pathol       Date:  1985-12       Impact factor: 6.394

7.  Barrett's esophagus. Comparison of benign and malignant cases.

Authors:  D B Skinner; B C Walther; R H Riddell; H Schmidt; C Iascone; T R DeMeester
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

8.  Evidence for a new model of tumor progression from carcinogenesis and tumor promotion studies with 7-bromomethylbenz[a]anthracene.

Authors:  J D Scribner; N K Scribner; B McKnight; N K Mottet
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

9.  Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.

Authors:  R A McKinnon; W M Burgess; P M Hall; S J Roberts-Thomson; F J Gonzalez; M E McManus
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

10.  Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.

Authors:  M G Sarr; S R Hamilton; G C Marrone; J L Cameron
Journal:  Am J Surg       Date:  1985-01       Impact factor: 2.565

View more
  9 in total

1.  Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Kuang-Den Chen; Li-Wen Hsu; Chia-Yun Lai; Ho-Ching Chiu; Ching-Yin Huang; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  World J Hepatol       Date:  2013-11-27

Review 2.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

3.  CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation.

Authors:  Hamid Zia; Graeme I Murray; Carrie A Vyhlidal; J Steven Leeder; Ahmed E Anwar; Marilyn M Bui; Atif A Ahmed
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

4.  Clinical and biochemical studies support smokeless tobacco's carcinogenic potential in the human oral cavity.

Authors:  Susan R Mallery; Meng Tong; Gregory C Michaels; Amber R Kiyani; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-21

Review 5.  Chemoprevention in Barrett's esophagus.

Authors:  Sumera Ilyas; Cathrine J DeMars; Navtej S Buttar
Journal:  J Gastrointest Cancer       Date:  2007

6.  Identification of key pathways and genes in Barrett's esophagus using integrated bioinformatics methods.

Authors:  Cong Zhang; Yujie Shen; Jiazheng Wang; Mingxia Zhou; Yingwei Chen
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

Review 7.  Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers.

Authors:  Nataliya Pidkovka; Olena Rachkevych; Abbes Belkhiri
Journal:  Oncotarget       Date:  2021-02-16

8.  Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients.

Authors:  King-Wah Chiu; Tsung-Hui Hu; Toshiaki Nakano; Kuang-Den Chen; Chia-Yun Lai; Li-Wen Hsu; Hui-Peng Tseng; Ho-Ching Chiu; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  Transplant Res       Date:  2013-04-23

9.  Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.

Authors:  C Martínez; E García-Martín; R M Pizarro; F J García-Gamito; J A G Agúndez
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.